Comparative Pharmacology
Head-to-head clinical analysis: APTIOM versus CELONTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APTIOM versus CELONTIN.
APTIOM vs CELONTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective enhancement of slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting excitatory neurotransmitter release.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Initial: 50 mg orally once daily; titrate at weekly intervals by 50 mg twice daily increments to maintenance dose of 200 mg twice daily (400 mg/day). Maximum: 400 mg twice daily (800 mg/day).
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life ranges from 20 to 48 hours (mean ~32 hours). Steady-state achieved within 5-7 days.
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
Primarily eliminated by hepatic metabolism, with approximately 95% excreted as metabolites in urine and <2% as unchanged drug. Fecal excretion accounts for about 5%.
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Category C
Category C
Anticonvulsant
Anticonvulsant